Related Experiment Video

Updated: Dec 30, 2025

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

5.9K

PCSK9 is a promising prognostic marker in patients with advanced NSCLC

Aldo Bonaventura1,2, Francesco Grossi3, Fabrizio Montecucco4,5

  • 1First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, viale Benedetto XV 6, 16132, Genoa, Italy. aldo.bonaventura@vcuhealth.org.

Cancer Immunology, Immunotherapy : CII
|January 16, 2020
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

591
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.5K

Related Experiment Videos

Last Updated: Dec 30, 2025

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

5.9K
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

591
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.5K

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

601
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
601

Articles linked to this work by shared authors, journal, and citation graph.

JCAD/KIAA1462: biology, pathophysiology, and translational perspectives in vascular disease.

Cardiovascular research·2026

Acute Myocarditis: From Pathophysiology to Risk-Stratified Management-A Clinical Review.

European journal of clinical investigation·2026

Beyond the primary endpoint: what VICTOR really tells us about vericiguat.

Expert opinion on pharmacotherapy·2026

Beta-Blockers After Myocardial Infarction With Preserved and Mildly Reduced Ejection Fraction: A Meta-Analysis With Trial Sequential Analysis.

European journal of clinical investigation·2026

Subcutaneous Adipose Tissue as a Metabolic Mirror: Transcriptomic Insights Into Glycaemic Dysregulation.

European journal of clinical investigation·2026

Management and Prognosis of Patients With Acute Pericarditis in the Emergency Department: A Retrospective, Single-Centre Study.

European journal of clinical investigation·2026

The CREM-IL-15 axis: decoding the persistence-exhaustion paradox in NK cell immunotherapy.

Cancer immunology, immunotherapy : CII·2026

Dual inhibition of tumor cells and tumor-associated neutrophils by anti-CXCR2 antibodies suppresses tumor growth and augments immunotherapy efficacy in ARID1A-deficient pancreatic cancer.

Cancer immunology, immunotherapy : CII·2026

Therapeutic targeting of CD47 using a tri-specific NK cell engager to inhibit multiple myeloma.

Cancer immunology, immunotherapy : CII·2026

Mast cells in tumors: dual roles and therapeutic potential.

Cancer immunology, immunotherapy : CII·2026

Preclinical efficacy of iPSC-derived MUC1-targeted CAR-NK cells against esophageal squamous cell carcinoma.

Cancer immunology, immunotherapy : CII·2026

HBO1 suppresses anti-tumor immunity of CD8⁺ T Cells in thyroid cancer by recruiting BRD4 to regulate VTCN1 expression.

Cancer immunology, immunotherapy : CII·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us